By Michael DavisThe promise of AI in healthcare is global, yet the regulatory landscape governing the movement and processing of sensitive health data across borders remains a labyrinth. For AI health companies seeking to scale internationally, navigating the intricate interplay between frameworks like HIPAA and GDPR is not merely a legal hurdle, but a fundamental enterprise procurement filter. This article dissects the complexities of cross-border health data transfer, outlining the critical compliance considerations for health IT professionals and policymakers alike.
The Dual Imperative: HIPAA and GDPR in Cross-Border AI Health
The expansion of AI health applications beyond national boundaries immediately confronts two of the world’s most stringent data protection regimes: the Health Insurance Portability and Accountability Act (HIPAA) in the United States and the General Data Protection Regulation (GDPR) in the European Union. While both aim to protect individual privacy, their scope, definitions, and enforcement mechanisms differ significantly, creating a compliance tightrope for companies like Nabla, a French AI health company, or US-based AI health platforms. HIPAA’s reach, primarily enforced by the HHS OCR, applies to covered entities (health plans, healthcare clearinghouses, and healthcare providers) and their business associates who create, receive, maintain, or transmit Protected Health Information (PHI). Crucially, HIPAA applies to US entities regardless of the data’s origin. This means a US-based AI health company processing health data from European patients, even if initially collected under GDPR, must still adhere to HIPAA’s Privacy Rule and Security Rule if it falls under HIPAA’s purview. Conversely, GDPR, enforced by the European Commission, protects the personal data of individuals within the EU and European Economic Area (EEA), regardless of where the data processing takes place. This extraterritorial reach means that any AI health company, whether based in the US or elsewhere, that processes the personal data of EU residents, or offers goods or services to them, must comply with GDPR. The EU AI Act, which entered into force on August 1, 2024, and has seen various provisions become applicable in phases, further introduces risk-based classifications for AI systems, with high-risk AI in health facing even more rigorous compliance obligations, including data governance requirements and human oversight. As of July 2026, the enforcement phase for the Act has begun, with transparency obligations for AI systems, including chatbot disclosure requirements, now applicable.
Navigating Data Transfer Mechanisms: SCCs and Adequacy Decisions
The primary challenge in cross-border health data transfer between the US and the EU lies in ensuring that data transferred from the EU to the US maintains a level of protection “essentially equivalent” to that guaranteed within the EU. As articulated by legal experts like I. Glenn Cohen, this equivalence is paramount. The European Commission has the power to issue “adequacy decisions,” declaring that a third country’s data protection laws provide an adequate level of protection. Historically, the EU-US Privacy Shield served this purpose but was invalidated. Following this, the EU-US Data Privacy Framework (DPF) was adopted by the European Commission in July 2023 as an adequacy decision, allowing for personal data transfers from the EU to certified US companies. While the DPF is currently a primary legal mechanism, US-EU data transfers also continue to rely on Standard Contractual Clauses (SCCs) as a legal mechanism. The DPF’s durability has recently been questioned following a June 2026 US Supreme Court ruling concerning the independence of the Federal Trade Commission, leading to renewed legal challenges. This ongoing challenge for US-EU data transfers requires careful consideration of where data is hosted, processed, and by whom. Deven McGraw has often highlighted the need for greater alignment and interoperability between privacy frameworks to facilitate responsible data sharing for health innovation.
Compliance as a Procurement Filter: Vendor Evaluation Frameworks
For health plans and large employers, the compliance posture of AI health apps is a critical enterprise procurement filter. Beyond the technical capabilities of an AI tool, its adherence to HIPAA, GDPR, and emerging regulations like the EU AI Act dictates its eligibility for adoption. This is where comprehensive compliance checklists and vendor evaluation frameworks become indispensable. Consider an AI health vendor like Nabla. If Nabla, operating in the EU, wishes to offer its AI solutions to a US health plan, it must demonstrate not only GDPR compliance but also how its operations align with HIPAA requirements if it handles PHI for a HIPAA covered entity. This often necessitates engaging with compliance automation platforms like Vanta and Drata, which help companies achieve and maintain certifications like SOC 2 and ISO 27001, often prerequisites for demonstrating robust security and privacy controls to potential partners. These certifications, while not direct HIPAA or GDPR compliance, signal a strong commitment to data security and governance, which are foundational to both regulatory regimes. The FTC also plays a role in overseeing data privacy practices, particularly concerning consumer health data not explicitly covered by HIPAA, adding another layer of scrutiny for AI health developers. Policymakers are increasingly focused on ensuring that AI innovations in health do not outpace regulatory safeguards, pushing for clearer guidelines on data governance, algorithmic transparency, and accountability. European Commission guidance on EU AI Act
Building Trust Through Robust Compliance
The convergence of HIPAA and GDPR, coupled with the advent of the EU AI Act, presents a formidable yet navigable challenge for AI health companies. For Health IT Professionals, the message is clear: robust, demonstrable compliance is no longer a mere legal obligation but a strategic imperative. It underpins trust, facilitates market access, and ultimately determines the viability of AI health solutions in large-scale deployments. The ability to articulate a clear, verifiable strategy for cross-border health data transfer, leveraging tools from companies like OneTrust, Vanta, and Drata, and expert legal counsel from firms such as Hogan Lovells and Dentons, will distinguish leading AI health apps. This proactive approach to regulatory adherence is essential for securing partnerships with discerning health plans and employers, ensuring that the transformative potential of AI in healthcare can be realized responsibly and ethically across international boundaries. HHS OCR guidance on HIPAA Privacy Rule GDPR official text
Frequently Asked Questions
What are the primary regulatory frameworks governing cross-border AI health data?
The two primary regulatory frameworks are the Health Insurance Portability and Accountability Act (HIPAA) in the United States and the General Data Protection Regulation (GDPR) in the European Union. Both aim to protect individual privacy, but they differ in scope, definitions, and enforcement mechanisms. The EU AI Act also introduces additional rigorous compliance obligations for high-risk AI in health.
How do HIPAA and GDPR apply to AI health companies operating internationally?
HIPAA applies to US entities, including AI health companies, if they fall under its purview, regardless of the data’s origin, meaning a US-based company processing European patient data must still adhere to HIPAA. GDPR applies extraterritorially to any AI health company that processes the personal data of EU residents or offers goods or services to them, regardless of where the company is based.
What mechanisms facilitate data transfer between the EU and the US for health data?
The EU-US Data Privacy Framework (DPF), adopted by the European Commission in July 2023, is currently a primary legal mechanism for personal data transfers from the EU to certified US companies. Additionally, Standard Contractual Clauses (SCCs) continue to be a legal mechanism for US-EU data transfers. These mechanisms aim to ensure that data transferred from the EU to the US maintains an equivalent level of protection.
Why is compliance with HIPAA, GDPR, and the EU AI Act important for AI health companies seeking investment or partnerships?
Compliance acts as a critical enterprise procurement filter for health plans and large employers. Beyond technical capabilities, adherence to these regulations dictates an AI tool’s eligibility for adoption and signals a strong commitment to data security and governance. Robust compliance builds trust and is often a prerequisite for demonstrating robust security and privacy controls to potential partners.
